Danish Healthtech Stock News

Novo Nordisk (CPSE:NOVO B) has transferred its clinical-stage Parkinson’s cell therapy program to AI-focused Cellular Intelligence. The move marks an exit from direct cell therapy development while keeping exposure to AI driven biotech through the partnership. The Parkinson’s therapy involved holds an FDA fast-track designation, placing it among higher-priority programs for potential patients. For investors tracking CPSE:NOVO B, this shift comes as the stock trades around DKK300.55, with a...

H+H International (CPSE:HH) opened 2026 with Q1 revenue of DKK 560 million and a reported loss per share of DKK 2.8, while on a trailing 12 month basis EPS stood at a loss of DKK 42.90 on revenue of DKK 2.63 billion. The company has seen quarterly revenue move from DKK 675 million and a loss per share of DKK 0.7 in Q1 2025 to DKK 560 million and a loss per share of DKK 2.8 in Q1 2026. Trailing 12 month net income shifted from a loss of DKK 662 million in Q4 2025 to a loss of DKK 697 million...

Q1 2026 earnings set the stage for North Media North Media (CPSE:NORTHM) has kicked off 2026 with Q1 revenue of DKK293.7 million and a basic EPS loss of DKK1.7, while trailing 12 month EPS stands at DKK8.17 on revenue of DKK1,279.2 million and net income of DKK148.2 million. Over the past year, revenue across reported periods has ranged between DKK286.4 million and DKK356.8 million per quarter, with basic EPS swinging from a loss of DKK10.12 to a gain of DKK5.29. That gives investors a wide...

H. Lundbeck (CPSE:HLUN B) has kicked off the Q1 2026 reporting season with recent quarterly figures that show Q4 2025 revenue of DKK6.1 billion and a basic EPS loss of DKK0.03, while trailing 12 month EPS sat at DKK3.22 on revenue of DKK24.6 billion. Over recent quarters, revenue has ranged from DKK5.5 billion in Q4 2024 to between DKK6.0 billion and DKK6.3 billion across the 2025 quarters. Quarterly EPS moved from DKK0.60 to DKK1.16 before the latest loss, setting up a mixed backdrop as you...

As the pan-European STOXX Europe 600 Index concluded a turbulent week with modest gains, investor sentiment was buoyed by easing geopolitical tensions and robust corporate earnings across the region. However, concerns over potential U.S. tariffs on EU goods introduced some volatility into the markets. In this environment, identifying stocks that may be priced below their intrinsic value estimates can offer opportunities for investors seeking to capitalize on market inefficiencies and strong...

Coloplast (CPSE:COLO B) Q2 2026 earnings in focus Coloplast (CPSE:COLO B) has kicked off its Q2 2026 reporting with Q1 figures that put hard numbers around the story, with revenue at about DKK7.0 billion, basic EPS of DKK6.21 and net income of DKK1.40 billion. These results are backed by trailing 12 month totals of DKK27.9 billion in revenue, DKK17.70 in EPS and DKK4.0 billion in net income. Over recent quarters the company has seen revenue hover in a tight band between DKK6.93 billion and...

New clinical data around Wegovy’s higher 7.2 mg dose is back in focus after Novo Nordisk (CPSE:NOVO B) released STEP UP sub-analyses showing deep, largely fat-driven weight loss and supportive real-world outcomes in women. See our latest analysis for Novo Nordisk. The new Wegovy data arrives after a busy few weeks for Novo Nordisk, with first quarter 2026 earnings, new distribution tie ups for Ozempic and oral GLP 1s, and the transfer of its Parkinson’s cell therapy program to an AI focused...

Rockwool A/S recently raised its 2026 revenue growth guidance to 3%–6% from 2%–4%, maintained its EBIT margin outlook at 13%–14%, and increased planned 2026 investments to about €700.00 million after seeing volume demand improve from March into the second quarter. The updated guidance suggests management now sees stronger momentum in underlying demand and is prepared to commit more capital to support that higher activity level through the rest of the year. We will now examine how Rockwool’s...

The European market has experienced a volatile but ultimately positive week, with the pan-European STOXX Europe 600 Index showing modest gains amid easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. have added pressure to the markets, creating an environment where insider ownership can be a reassuring factor for investors looking at growth companies. In such conditions, stocks with high insider ownership might offer...

Bavarian Nordic (CPSE:BAVA) is back in focus after securing US$97 million in contract options from the U.S. government for freeze dried smallpox vaccines and lifting its full year 2026 financial guidance. See our latest analysis for Bavarian Nordic. At a share price of DKK194.6, Bavarian Nordic has seen a 1-year total shareholder return of 16.84%, while the 5-year total shareholder return is down 28.27%. This suggests that recent momentum has improved compared with a weaker longer term...

DFDS (CPSE:DFDS) has drawn investor attention after reporting first quarter 2026 results that showed a narrower net loss and confirming full year EBIT guidance, supported by comments on improving freight traffic and profitability recovery. See our latest analysis for DFDS. The earnings update and confirmed EBIT guidance have arrived alongside a sharp improvement in momentum, with the share price delivering a 27.05% 1 month return and a 49.47% year to date share price return. The 1 year total...

We wouldn't blame Dampskibsselskabet Norden A/S ( CPH:DNORD ) shareholders if they were a little worried about the fact...

Recent share performance and business scale ISS (CPSE:ISS) has caught investor attention after a strong year, with the stock showing a 65.1% total return over the past 12 months and 21.9% year to date. Over the past week the share price return is 10.1%, with gains of 8.9% over the past month and 4.8% over the past 3 months. The company reports DKK 84,684 million in revenue and DKK 2,603 million in net income. See our latest analysis for ISS. With ISS shares now trading at DKK262.8 and showing...

A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...

We wouldn't blame Danske Bank A/S ( CPH:DANSKE ) shareholders if they were a little worried about the fact that Carsten...

Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...

Why Vestas Wind Systems is back on investors’ radar Vestas Wind Systems (CPSE:VWS) is drawing fresh attention after reporting first quarter 2026 earnings, with sales of €3,966 million and net income of €82 million, alongside confirmed full year revenue and margin guidance. The update also arrived alongside new turbine orders in Germany, giving investors fresh information on both current profitability and the future project pipeline for one of the sector’s established wind equipment...

Why the JCSI-35 launch matters for NKT stock NKT (CPSE:NKT) has drawn fresh investor attention after introducing its IEEE-qualified JCSI-35 medium-voltage cold-shrink splice in North America, a product aimed at grid operators across the United States and Canada. The launch ties directly to NKT’s effort to grow its accessories offering in a copper wire and cable market that is projected to expand, as well as reinforcing its role in large infrastructure projects such as Champlain Hudson Power...

MT Højgaard Holding (CPSE:MTHH) has put fresh numbers on the table for FY 2025, with Q4 revenue of DKK 2.5b and basic EPS of DKK 10.08 alongside net income from continuing operations of DKK 77.7m. Over recent quarters the company has seen revenue move between DKK 2.4b and DKK 3.1b and quarterly EPS range from DKK 9.13 to DKK 14.81, which sets expectations around how a trailing net margin of 3.1% will shape investor views on the quality and resilience of those earnings. See our full analysis...

Q1 earnings as the key trigger Novozymes (CPSE:NSIS B) is back in focus after reporting first quarter 2026 results, with sales of €1,119.3 million and net income of €199.1 million compared with the same period a year earlier. See our latest analysis for Novozymes. The Q1 release appears to have steadied sentiment, with a 1-day share price return of 2.25% partly offsetting weaker recent momentum, including a 1-year total shareholder return of 12.68% and a 5-year total shareholder return of...

Genmab (CPSE:GMAB) has drawn fresh attention after its first quarter 2026 report, where sales reached US$896 million but net income dropped to US$53 million, alongside a negative immediate share price reaction. See our latest analysis for Genmab. The weak 1 day share price return of 6.74% and 30 day share price return of 8.30% follow a Q1 update where revenue moved higher but net income declined sharply, leaving the current share price at DKK1,640. Over a longer horizon, the 1 year total...

Why Vizient’s contract matters for Coloplast (CPSE:COLO B) Coloplast (CPSE:COLO B) just secured an Innovative Technology contract with Vizient for its Biatain Silicone Fit wound dressing, putting the product in front of a broad network of US hospitals and care providers. This recognition reflects feedback from Vizient’s client-led councils and signals that Biatain Silicone Fit has characteristics US healthcare buyers consider differentiating. This development could influence how investors...

If you are wondering whether Pandora at DKK 537.6 is priced for a recovery or still carries more risk than reward, this breakdown will help you frame what the current share price might be implying. The stock has returned 8.2% over the last week and 14.0% over the last month, set against a year-to-date return of a 22.7% decline and a 45.4% decline over the last year. Recent coverage around Pandora has focused on whether the current share price aligns with its fundamentals, as investors weigh...

A.P. Møller & Co. Mærsk (CPSE:MAERSK B) is back in focus after first quarter 2026 results showed profit pressure alongside higher fuel and operating costs linked to Middle East disruptions, including the war in Iran and constrained shipping routes. See our latest analysis for A.P. Møller - Mærsk. The stock has pulled back recently, with a 7 day share price return of 7.22% and a 30 day share price return of 11.34% after the weaker Q1 net income and rising fuel costs. However, the 1 year total...